Skip to content

AdaptHealth AHCO Respiratory Health — Goodwill

Other segment segments

Sleep Health
$1.6B+1.1%
Wellness at Home
$192.19M+15.9%
Diabetes Health
$83.8M-60.4%

Similar metrics at other companies

LivaNova logo
LIVNCardiopulmonary — Goodwill
$386.84M+6.5%
Ziff Davis logo
ZDHealth & Wellness — Goodwill
$403.87M-0.1%
Ashland logo
ASHLife Sciences — Goodwill
$462M-42.8%
ExlService Holdings logo
EXLSHealthcare and Life Sciences — Goodwill
$189.57M0.0%
Leidos Holdings logo
LDOSHealth — Goodwill
$1.34B
Voya Financial logo
VOYAHealth Solutions Segment — Goodwill
$343M0.0%

Other financials

Income statement

See full
Revenue$819.8M+5.4%
Gross profit$111.5M-7.4%
Operating income$5.5M-76.3%
Net income-$16.0M-123%
EPS (diluted)-$0.12-140%

Balance sheet

See full
Cash & equivalents$48.0M-10.6%
Total debt$2.0B-4.9%
Total equity$1.5B-3.9%
Total assets$4.4B-0.3%

Cash flow

See full
Operating cash flow$93.7M-1.9%
CapEx$121.2M+26.8%
Free cash flow-$27.5M-47,297%

Valuation

See full
Market cap$1.36B+20.5%
Enterprise value$3.32B+4.3%
P/S0.4×+0.1×

Profitability

See full
Gross margin18.3%-1.6pp
Operating margin8%+6.9pp
Net margin-2.4%-5.1pp
FCF margin5.8%-2.6pp

Returns & leverage

See full
Return on equity-5.2%-10.8pp
Debt / equity1.3×0.0×
Current ratio0.9×-0.4×

Where this comes from

Reported directly by AdaptHealth in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: AdaptHealth’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about AdaptHealth's respiratory health — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AdaptHealth's respiratory health — goodwill?
AdaptHealth (AHCO) reported respiratory health — goodwill of $692.66M in Q1 2026.
How has AdaptHealth's respiratory health — goodwill changed year-over-year?
AdaptHealth's respiratory health — goodwill increased by 2.4% year-over-year, from $676.75M to $692.66M.
What does respiratory health — goodwill mean?
This is the intangible asset value recorded when the purchase price of an acquired respiratory business exceeds the fair value of its identifiable net assets. It reflects the premium paid for market share, brand reputation, and synergies within the segment.